(Q56852150)

English

Tolvaptan

No description defined

In more languages

Statements

scholarly article

0 references

1 reference

Europe PubMed Central

Tolvaptan (English)

0 references

1

object named as

Greg L. Plosker

0 references

publication date

March 2010

0 references

0 references

70

0 references

4

0 references

443-454

0 references

https://scigraph.springernature.com/pub.10.2165/11204630-000000000-00000

0 references

Hyponatremia, fluid-electrolyte disorders, and the syndrome of inappropriate antidiuretic hormone secretion: diagnosis and treatment options

1 reference

https://api.crossref.org/works/10.2165%2F11204630-000000000-00000

21 January 2018

Intravenous conivaptan

1 reference

https://pubmed.ncbi.nlm.nih.gov/20205486

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hyponatremia in the neurosurgical patient: epidemiology, pathophysiology, diagnosis, and management

1 reference

https://pubmed.ncbi.nlm.nih.gov/20205486

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure

1 reference

https://pubmed.ncbi.nlm.nih.gov/20205486

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Weight changes after hospitalization for worsening heart failure and subsequent re-hospitalization and mortality in the EVEREST trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20205486

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Diagnosis and management of hyponatremia in acute illness

1 reference

https://pubmed.ncbi.nlm.nih.gov/20205486

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics, pharmacodynamics, and safety of tolvaptan, a nonpeptide AVP antagonist, during ascending single-dose studies in healthy subjects

1 reference

https://pubmed.ncbi.nlm.nih.gov/20205486

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model

1 reference

https://pubmed.ncbi.nlm.nih.gov/20205486

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Vasopressin V2 Receptor Blockade With Tolvaptan Versus Fluid Restriction in the Treatment of Hyponatremia

1 reference

https://pubmed.ncbi.nlm.nih.gov/20205486

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction

1 reference

https://pubmed.ncbi.nlm.nih.gov/20205486

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetic and pharmacodynamic interaction between tolvaptan, a non-peptide AVP antagonist, and furosemide or hydrochlorothiazide

1 reference

https://pubmed.ncbi.nlm.nih.gov/20205486

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of tolvaptan on dyspnoea relief from the EVEREST trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/20205486

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hyponatremia treatment guidelines 2007: expert panel recommendations

1 reference

https://pubmed.ncbi.nlm.nih.gov/20205486

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Non-peptide arginine-vasopressin antagonists: the vaptans

1 reference

https://pubmed.ncbi.nlm.nih.gov/20205486

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/20205486

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction

1 reference

https://pubmed.ncbi.nlm.nih.gov/20205486

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epidemiology of hyponatremia.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20205486

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/20205486

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapeutic potential of vasopressin receptor antagonists.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20205486

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/20205486

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of two doses and dosing regimens of tolvaptan in congestive heart failure

1 reference

https://pubmed.ncbi.nlm.nih.gov/20205486

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacology of vasopressin antagonists

1 reference

https://pubmed.ncbi.nlm.nih.gov/20205486

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program

1 reference

https://pubmed.ncbi.nlm.nih.gov/20205486

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/20205486

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

1 reference

https://pubmed.ncbi.nlm.nih.gov/20205486

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/20205486

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hyponatremia: current treatment strategies and the role of vasopressin antagonists

1 reference

https://pubmed.ncbi.nlm.nih.gov/20205486

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia

1 reference

https://pubmed.ncbi.nlm.nih.gov/20205486

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/11204630-000000000-00000

0 references

Dimensions Publication ID

0 references

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q56852150&oldid=1405491633"